Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
RANCHO CORDOVA, Calif., Jan. 02, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Chris Xu, Ph.D., chief executive officer, will be presenting at Biotech Showcase on Tuesday, January 9, 2018 at 4:00pm PST. The conference is being held January 8-10, 2018 at the Hilton San Francisco Union Square.
A live webcast of the presentation will be available at:
https://event.webcasts.com/starthere.jsp?ei=1176627&tp_key=d941414f85. The webcast will be archived for 90 days.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
